Compare Etsy Inc (ETSY) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Etsy Inc vs TransMedics Group Inc — how do they compare? Etsy Inc trades at $76.71 (market cap $6.90B), while TransMedics Group Inc trades at $77.87 (market cap $2.74B). The key difference: Etsy Inc is far larger — about 2.5× TransMedics Group Inc's market cap, and Etsy Inc is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Etsy Inc for 67 Days and TransMedics Group Inc for 24 Days on average.
| ETSY | TMDX | |
|---|---|---|
Market Cap | $6.90B | $2.74B |
Volume | 2,923,867 | 949,331 |
Sector | Consumer Cyclical | Health |
52-Week High | $87.03 | $150.42 |
52-Week Low | $44.05 | $61.99 |
Typical Hold Time | 67 Days | 24 Days |
Enterprise Value | $8.85B | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ETSY trades at $75.14, up 5.11% today, reflecting strong momentum. The stock shows a bullish technical outlook with consistent earnings beats and a 53.33% analyst buy rating. Recent news highlights AI integration to enhance personalization and renewed payment partnerships, supporting growth. Revenue reached $2.88B in 2025, though net income margin dipped to 5.65%. Cash flow improved with $593.18M net inflow in 2025, but high debt and negative equity pose financial risks.
The outlook is cautiously optimistic with a consensus price target of $85.94 offering ~14% upside. Strengths include robust gross margins and strategic AI initiatives, but risks involve elevated valuation multiples, competitive pressures, and sensitivity to consumer spending trends. Investors should weigh growth potential against balance sheet concerns.
TMDX trades at $79.00, down 2.55% amid bearish technical signals. The stock shows strong profitability with 22.69% net margin and 36.28% ROE, though recent earnings misses and margin compression from 2025 to 2026 raise concerns. Analyst consensus remains bullish with a $99.75 price target, but multiple legal investigations into fiduciary duties create uncertainty. Revenue growth continues with 2026 guidance at $668M.
The stock presents a growth opportunity with analyst upside potential, but faces near-term headwinds from earnings volatility and legal scrutiny. Execution on 2026 guidance and resolution of governance concerns will be critical for sustained momentum. Current valuation at 20.47 P/E appears reasonable given growth prospects if operational targets are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Etsy Inc
Etsy operates a top-10 e-commerce marketplace operator in the U.S. and the U.K., with sizable operations in Germany, France, Australia, and Canada. The firm dominates an interesting niche, connecting buyers and sellers through its online market to exchange vintage and craft goods. With $13.5 billion in 2021 consolidated gross merchandise volume, the firm has cemented itself as one of the largest players in a quickly growing space, generating revenue from listing fees, commissions on sold items, advertising services, payment processing, and shipping labels. As of the end of 2021, the firm connected more than 96 million buyers and more than 7.5 million sellers on its marketplace properties: Etsy, Reverb (musical equipment), Elo7 (crafts in Brazil), and Depop (clothing resale).
Read more on ETSY →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
